Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 665

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 665
---
2, 2023 and 2024 to extend the expiration date and shall expire on December 30, 2025.

F-17

Preferred Stock

In 2020, the Company designated 45,000 shares
of its preferred stock with par value of $0.001 per share as Series A Junior Participating Preferred Stock. The remaining 9,955,000 shares
of preferred stock with par value of $0.001 remain undesignated. None of the preferred shares were issued and outstanding at December 31,
2024 and 2023.

NOTE 10 – INCOME TAXES

Loss before income taxes summarized by region
was as follows:

    (in thousands) 
    December 31, 2024  
    December 31, 2023 
  
    United States 
    $22,603  
    $20,286 
  
    Foreign 
     19,479  
     9,722 
  
    Total loss before income taxes 
     42,082  
     30,008 

The provision for income taxes consists of the
following components:

     December 31, 2024  
     December 31, 2023 
  
    Current expense (benefit) 
    $-  
    $- 
  
    Federal 
     -  
     - 
  
    State 
     -  
     - 
  
    Foreign 
     -  
     - 
  
    Current income tax expense 
     -  
     - 

    Deferred expense (benefit) 
     -  
     - 
  
    Federal 
     -  
     - 
  
    State 
     -  
     - 
  
    Foreign 
     -  
     - 
  
    Deferred income tax 
     -  
     - 
  
    Net deferred taxes 
    $-  
    $- 

A reconciliation of income tax benefit computed
using the federal statutory income tax rate to the Company’s tax expense is as follows:

    (in thousands, except percentage) 
    December 31,  2024  
    December 31,  2023 
  
    Federal tax benefit at statutory rate (21%) 
    $(8,837) 
    $(6,302)
  
    Stock-based compensation 
     1,